Precision-oncology diagnostics company applying gene-expression biology to liquid-biopsy sequencing through its ExpressCT fragmentomics platform and biomarker services.
At a glance
- Founded: 2011
- HQ: Durham
- Sector: Biotech
- Stage: Series C
- Total raised: $2.0M
- Affiliation: UNC
GeneCentric record
Sourced from original public records. Each round and signal links to the document it was taken from.
Founders
- Charles M. PerouFounder and Director
- David Neil HayesObserver and Founder
- Myla Lai-GoldmanCo-Founder & Chair
Funding history
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Jun 2025 | Venture | $2M | — | Source |
Investors
Recent signals
- 2026-07-08GeneCentric launches ExpressCT Rewind for retrospective liquid-biopsy expression analysisGlobeNewswire / GeneCentric
- 2026-07-08GeneCentric launches ExpressCT Rewind for existing liquid-biopsy dataGeneCentric
Follow GeneCentric.
A watchlist, notes and questions on this company open with a free account.
Listed roles
All Triangle rolesChecking listed roles…